These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27756965)

  • 21. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
    Pearson EC; Woosley RL
    Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y; Swartzon M; Justo D
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Torsades de pointes following cardioversion: case history and literature review.
    Spearritt D
    Aust Crit Care; 2003 Nov; 16(4):144-9. PubMed ID: 14692159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
    Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
    Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ciprofloxacin-induced torsade de pointes.
    Flanagan MC; Mitchell ES; Haigney MC
    Int J Cardiol; 2006 Nov; 113(2):239-41. PubMed ID: 16386810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of prolonged QT interval and torsades de pointes in the intoxicated patient.
    Kan AA; de Lange DW; Donker DW; Meulenbelt J
    Neth J Med; 2014 Apr; 72(3):119-26. PubMed ID: 24846924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents.
    Jardin CG; Putney D; Michaud S
    Ann Pharmacother; 2014 Feb; 48(2):196-202. PubMed ID: 24301687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loperamide Induced Recurrent Torsades de Pointes: A Case Report.
    Jackson GG; Lopez CR; Bermudez ES; Hill NE; Roden DM; Ely EW; Stollings JL
    J Pharm Pract; 2022 Oct; 35(5):791-795. PubMed ID: 33779357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Termination of drug-induced torsades de pointes with overdrive pacing.
    Charlton NP; Lawrence DT; Brady WJ; Kirk MA; Holstege CP
    Am J Emerg Med; 2010 Jan; 28(1):95-102. PubMed ID: 20006210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Iatrogenic torsade de pointes induced by thioridazine].
    Paoloni P; Ciliberti D; Blasi N; Capone P
    Minerva Cardioangiol; 1992 Jun; 40(6):245-9. PubMed ID: 1407620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged QT: A rare cause of cardiac arrest.
    Carlquist J
    JAAPA; 2015 Aug; 28(8):. PubMed ID: 26208008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic methadone therapy complicated by torsades de pointes: a case report.
    Pimentel L; Mayo D
    J Emerg Med; 2008 Apr; 34(3):287-90. PubMed ID: 18022786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Open-loop, clockwise QT-RR hysteresis immediately before the onset of torsades de pointes in type 2 long QT syndrome.
    Nakaji G; Fujiwara M; Fukata M; Yasuda S; Odashiro K; Maruyama T; Akashi K
    J Electrocardiol; 2010; 43(3):261-3. PubMed ID: 20079908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [An unusual cause of cardiac arrest].
    Campana A; Manzo M; Brigante M; Marrazzo N; Melchiorre G
    Ital Heart J Suppl; 2003 Jun; 4(6):510-3. PubMed ID: 19400057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes.
    Isbister GK; Balit CR; Macleod D; Duffull SB
    J Clin Psychopharmacol; 2010 Aug; 30(4):391-5. PubMed ID: 20531221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
    Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
    Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL; Pollard CE; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator.
    Kaźmierczak J; Peregud-Pogorzelska M; Rzeuski R
    Pacing Clin Electrophysiol; 2007 Aug; 30(8):1043-6. PubMed ID: 17669094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired long QT syndrome from stress cardiomyopathy is associated with ventricular arrhythmias and torsades de pointes.
    Madias C; Fitzgibbons TP; Alsheikh-Ali AA; Bouchard JL; Kalsmith B; Garlitski AC; Tighe DA; Estes NA; Aurigemma GP; Link MS
    Heart Rhythm; 2011 Apr; 8(4):555-61. PubMed ID: 21146632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
    Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.